Pharmacokinetics of PN-232 in Healthy Volunteers

NCT04819620 ↗

Phase 1 Completed 48 enrolled Protagonist Therapeutics, Inc.

RandomizedSequentialTriple-blindTreatment

Summary

This Phase 1 study is designed to determine the safety, tolerability and pharmacokinetics of PN-232 in healthy volunteers. It is a first-in-human (FIH) study for PN-232 that will be conducted in three parts. Part 1 is a single ascending dose study, Part 2 is multiple ascending dose study, and Part 3 is crossover solid dose comparison and effect of food study.

Timeline

Start: 2021-05-13
Primary completion: 2021-12-17
Completion: 2022-06-16

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PN-232	Unknown	—	—

Indications

No indication recorded.